AsiaOne Magazine April-May 2018 Issue

iconic
healthcare
CIPLA
Touching Lives with Care
Since 1935 when Cipla was incorporated, the pharmaceutical giant pioneered bulk
drug production in India and is associated with the landmark Indian Patents Act of
1970 alongside taking a historic international stance on the price and availability of
antiretroviral drugs for HIV treatment in 2000-2001
With over 1500+
p r o d u c t s
across various
therapeutic
categories, 50+ dosage
forms, backed by a workforce
of 23,000+ together with a
strong distribution network
comprising over 3,000
stockists reaching out to
over 7,00,000 chemists and
a turnover of USD 2.2 billion,
Cipla has registered a strong
presence in over 100 countries
including key markets of India,
South Africa, the US, South-
East Asia, Middle-East, Latin
America, Africa, Australia,
New Zealand and Russia-CIS.
The company has adopted the
direct-to-market approach in
17 different markets including
Algeria, Morocco, Malaysia,
Vietnam, Yemen and Sri Lanka
among others. With a strong
commitment to provide access
to Africa and several Least
Developed Countries, Cipla has
12 distinct divisions reaching
out to more than 20 specialties
from general practitioners to
super-specialists. Seven of
its brands feature in the top
100 list across Respiratory,
Urology and Antiretroviral
therapy areas. Cipla has
over 43 cGMP compliant
manufacturing facilities.
and medical devices. Cipla’s
extensive product portfolio
includes the world’s largest
range of respiratory drugs,
dosage forms and devices
for COPD and Asthma. The
company owns five dedicated
manufacturing facilities for
respiratory products and is
currently the third largest
manufacturer of pMDIs in the
world. From the Transparent
Rotahaler launched in 1996
to Multi-haler, Autohaler2,
Zerostat and Zerostat VT,
Babymask and Infantmask,
Nasal sprays and the widest
range of Dry Powder Inhaler
devices including the new
generation Revolizer and
Synchrobreathe, the breathactuated
inhaler with a dose
counter, Cipla has end-to-end
capability across respiratory
care.
Glorious Footprints
The coveted Cipla Archives
is in the design phase and
will feature documents,
photographs and interviews,
among other relevant
material to showcase
Cipla’s history and serve as
a forum for discussions on
Cipla’s role in the evolution
of the self-sufficient Indian
pharmaceutical industry.
Full Control of the
Value Chain
Globally, Cipla has about
100 patents including drug
substances, drug products,
platform technologies, IP on
polymorphs and crystallinity,
172 | ASIA ONE | april-mAY 2018